Vijay Nambi, MD Department of Internal Medicine, The Cleveland Clinic
Byron J. Hoogwerf, MD Director, Internal Medicine Residence Program, Department of Endocrinology, The Cleveland Clinic
Dennis L. Sprecher, MD Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, The Cleveland Clinic
Address: Dennis L. Sprecher, MD, Department of Cardiology, C51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail sprechd@ccf.org
Dr. Sprecher has indicated that he has received grant or research support from the Astra/Zeneca/Merck corporation and is also on its speakers’ bureau. He also serves as a consultant for International Medical Innovations, Inc.
This paper discusses treatments that are not approved by the US Food and Drug Administration for some of the uses under discussion.
ABSTRACTThe cluster of hypertriglyceridemia, hyperinsulinemia, obesity, and hypertension markedly increases the risk of coronary artery disease. Although no treatments target this syndrome specifically, treatment of each aspect of the cluster is important. Prevention—weight loss and physical activity—is key.
